Show simple item record

2020-06-03Zeitschriftenartikel
Repositioning of the global epicentre of non-optimal cholesterol
dc.contributor.authorNCD Risk Factor Collaboration
dc.date.accessioned2023-12-12T15:48:49Z
dc.date.available2023-12-12T15:48:49Z
dc.date.issued2020-06-03none
dc.identifier.other10.1038/s41586-020-2338-1
dc.identifier.urihttp://edoc.rki.de/176904/11415
dc.description.abstractHigh blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol—which is a marker of cardiovascular risk—changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million–4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectcardiovascular diseaseseng
dc.subjectrisk factorseng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleRepositioning of the global epicentre of non-optimal cholesterolnone
dc.typearticle
dc.identifier.urnurn:nbn:de:0257-176904/11415-6
dc.type.versionpublishedVersionnone
local.edoc.container-titleNaturenone
local.edoc.container-issn1476-4687none
local.edoc.pages24none
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.nature.com/none
local.edoc.container-publisher-nameSpringer Naturenone
local.edoc.container-volume528none
local.edoc.container-issue7810none
local.edoc.container-reportyear2020none
dc.description.versionPeer Reviewednone

Show simple item record